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In Vitro Mucin-Producing Models to Study Cystic Fibrosis 




Cystic Fibrosis (CF) is a genetic disease featuring a mutation in the CFTR gene that leads 
to a buildup of thick clumps of high-molecular-weight glycoproteins (mucins/MUCs) in the lungs 
and the intestines. This causes difficulty breathing, frequent infections, poor growth, nutrient 
malabsorption, and ultimately death. Although pulmonary complications are the most life 
threatening and the most studied, investigating intestinal physiology may provide better insight 
into the altered mucus properties and systemic effects of CFTR dysfunction. Our goal was to 
establish a model system to study the effects of CFTR function on gut mucus and to further 
characterize mucus properties in the intestine. The HT29 cell line, derived from a colon 
adenocarcinoma, was used in this project as it has previously proven to express both CFTR and 
mucin genes. To determine the most appropriate culture conditions and optimize expression of 
mucins and CFTR, HT29 cells were grown in different media, and the validity of the model was 
evaluated through resistance measurements, mucin biochemical assays (e.g., 
immunohistochemical staining and Western blotting), and histology. CFTR Cl- secretion was 
measured by Ussing chamber following forskolin stimulation, but the formation of an intercellular 
lumina “blister” impeded the traditional measurement of CFTR function.  Following culture 
conditions optimization, a CFTR knockout was generated through CRISPR/Cas9 lentivirus 
infection and confirmed via protein analysis. In parallel, healthy wild-type (WT) cells were 
compared to cells where CFTR was pharmacologically inhibited (i.e., CF-like cells) and showed 
differences in mucin concentrations. Our data suggests these mucin-producing cell lines can 
function as relevant in vitro models to study the CF gut mucus phenotype. Investigating pure 
mucus in an environment devoid of inflammatory cells and/or fecal matter can help focus on 
mucins’ abnormal properties and reveal novel pharmaceutical targets. A treatment targeting 
mucins or reversing the abnormal mucus phenotype would be mutation agnostic (i.e., independent 
of genotype) and therefore would have the potential to slow the progression of the disease and 
benefit all patients with CF. 
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Cystic Fibrosis (CF) is a chronic life-threatening disease generally caused by a mutation in 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene that decreases the ability of 
cells to effectively secrete chloride anions.1 Subsequent water hyperabsorption in response to the 
ionic influx leads to an external buildup up of high-molecular-weight glycoproteins (mucins or 
MUCs) with decreased viscoelasticity unable to be cleared.2 Mucins are critical macromolecules 
responsible for the viscoelastic properties of mucus and can accumulate quickly; the worst effects 
of which are seen in the lungs and intestinal tract.3 This mucus buildup restricts organ function by 
obstructing the airway ducts and digestive tract, making it difficult to pass air and absorb nutrients 
necessary for growth and development.1 
Recently, Trikafta, a triple combination therapy of CFTR modulators has made headlines 
for being approved for patients carrying a copy of the most common mutation (∆F508) and can 
potentially treat 80 % of CF cases.4 However, a prominent issue remains for patients who do not 
qualify for modulator therapy (e.g., rare mutations or nonsense mutations). A general cure for the 
disease has yet to be fully investigated, but a gene independent treatment would be ideal to 
potentially benefit the entire CF patient community. 
While both airway disease progression and respiratory complications have proven to be the 
most life-threatening concern for the disease and our previous work enlightened the role played by 
CFTR on airway mucins, investigating the effects of CFTR function on intestinal mucus may 
provide insight into the shared mucus properties and reveal novel mucin-based targets. The 
traditional mouse model used to study CF has posed problems in studying intestinal mucus because 
it often presents an increased bacterial burden with inflammation and obstruction.5 In vivo models 
are therefore not preferred as these additional phenotypic effects make it more difficult to study 
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pure mucus. An in vitro model instead provides more consistency allowing for reproducibility. To 
further investigate mucus properties and the effects of CFTR malfunction, we aim in this study to 
determine the best conditions for developing and studying a cell line that models the intestinal 
epithelium. 
 HT29 is a human colon adenocarcinoma cell line composed of enterocytes and mucus-
secreting goblet cells with the potential to accurately model CF due to high mucus production and 
expression of functioning CFTR.6&7 HT29 cells are semi-polarized to model the distinction in the 
human intestines of apical and basal sides. Cancer cells are generally unpolarized and stack on top 
of each other, but it is possible to induce polarization in HT29 to form a monolayer.8 The HT29-
MTX-E12 line was differentiated with methotrexate to further stimulate goblet cell metaplasia and 
better mimic colonic crypts.9 This line should be ideal to study the impact of CFTR function on 
mucin production and organization because of these factors.10 
It is important to ensure this differentiated line is as polarized as possible, so it pumps 
chloride and secretes mucins towards the apical lumen. Because HT29 is a cancer cell line, it tends 
to form multilayers rather than a single monolayer (Figure 1A). A balance must be established of 
an ordered epithelium that still possesses the features of colonic crypts. Since the HT29 line is 
initially only semi-polarized, it can form intercellular lumina (ITCL) which trap mucus and 
separate the cells (Figure 1B). Some cells secrete their wastes and products in towards what should 
be the basal side or towards other cells because they have not fully differentiated and/or polarized.8 
These ITCL make it difficult to accurately collect entrapped mucus as it is not open to the apical 
lumen, and they weaken tight junctions (i.e., lower resistance). In vivo, the intestinal epithelium 






Figure 1. HT29 Polarization Influenced by Media Conditions. 
A) Weakly polarized cell line. B) Semi-polarized cells with the presence of an ITCL. C) Polarized 
monolayer of cells. Modified from Hekmati et al.8  
 
  For 2D-planar models, cell polarization and resistance depend on environmental factors, 
such as the quality of the media, gas concentration, pH, and maintaining a sterile environment. 
While gas concentration, pH, and sterile environment are mostly standardized for in vitro models, 
we spent time testing different media to optimize the polarization and resistance of HT29-MTX-
E12 cells. While McCoy’s 5A is a standard base media for much of mammalian cell culture, 
Dulbecco’s Modified Eagle's Medium (DMEM) has come to be the most common HT29 cell 
culture media.12 L-alanyl-L-Glutamine is incorporated into DMEM Glutamax as several studies 
have signified its prevalence in forming strong tight junctions and healthier cells because it does 
not degrade into ammonia as quickly as regular glutamine in most media.13 The standard media 
encloses a low glucose concentration, but glucose supplements are offered. Our lab initially used 
high-glucose DMEM Glutamax based on a previous study indicating increased mucus production, 
but other studies suggested the absence of glucose lead to better gut epithelium differentiation.14 
Initial media testing in our lab also suggested better cell morphology when using lower glucose 
concentrations. RPMI 1640 is another cell culture media with intermediate glucose concentration 
that can induce strong polarity over time and can lead to a complete monolayer of HT29 cells.8 
A B C 
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These media were compared to culture the HT29 cell line and to study the impacts on cell structure 
and organization as well as mucin production and CFTR function. 
 Even with the HT29-MTX-E12 differentiated cell line, mucus production is lower than in 
vivo.15 Several studies point to treatment with DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester) and mechanical stimulation as a method to increase goblet cell 
differentiation and promote the production of even more mucus.7  Interestingly, a study showed 
that goblet cell metaplasia, known to be associated with increased mucin concentrations, was 
correlated with decreased CFTR expression.3 For our project, the proper balance between CFTR 
expression/function and mucin secretion must be achieved to further study the effects of CFTR 
loss-of-function mutations on mucus production and mucus properties. For that, we tested different 
media to determine the best conditions for our study. 
Different media recipes as well as treatment with and without DAPT and mechanical 
stimulation were investigated with a goal to obtain a well-differentiated cell layer mimicking the 
gut epithelium and to establish the best model to study mucus alterations in response to CFTR loss 
and gain of function with regards to the cystic fibrosis gut disease.  
In in vivo conditions, the intestinal epithelium dominantly expresses MUC2 with traces of 
MUC5B and MUC5AC, the dominant mucin of the stomach that is also expressed in the lungs 
following pathogen infection.16 MUC2 and MUC5AC as well as MUC5B, MUC6, and other less 
significant mucins are classified as gel-forming mucins. They are stored in secretory granules that 
are then released in response to agonists and expand in response to pH and ion level changes.17 
Once secreted, it is believed that the mucins polymerized in the endoplasmic reticulum and golgi 
can unfold to form net-like spreads over cells.18 Studies have indicated that MUC2 forms dimers 
of trimers leading to hexagonal rings which may strongly impact the mucin network 
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ultrastructure.19 However, MUC2 has been suggested to remain tethered to the cell membrane 
needing additional cleavage before total release.20 Understanding these mucin properties is 
important to developing a mucin-based treatment centered on mitigating mucus abnormalities and 
could apply not only to CF but also to diseases with abnormal mucus properties like COPD and 
asthma for the lungs or IBD and Crohn’s disease for the GI tract. 
 Recently, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-
associated (Cas) protein 9 system (CRISPR/Cas9) has become an increasingly popular tool to 
assist with DNA editing. This combination introduces double-strand breaks at precise sites 
determined by programmable sequence-specific guide RNAs (sgRNAs).21 While it has proven 
value to clinical gene therapy studies for cancer and other diseases, it can also be used in vitro to 
modify cell lines. The non-homologous end joining (NHEJ) repair path of the double strand 
break is especially useful with CRISPR/Cas9 as it allows for efficient insertions and deletions, 
creating early stop mutations to fully knock out the expression of a specific gene. Compared to 
homologous-directed-repair (HDR), common for reverse back point mutation, NHEJ has a 
higher probability of occurring with less random chance.22 Increasing our probability of gene 
editing is especially important for the HT29 cell lines as it is triploid, and therefore, requires 
mutations across all three chromosomes to initiate a CFTR knockout.23 The CRISPR/Cas9 
system produces stable mutations that persist across multiple passages since the mutation is fully 
incorporated into the genome of successfully manipulated cells.24 We used the CRISPR/Cas9 
method to generate a CFTR-KO HT29 cell line, and in parallel, we mimicked a CF-like 
phenotype by using bumetanide/dimethylamiloride (DMA) on WT HT29 cells to temporarily 
block chloride and bicarbonate secretion.25 
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 The effects of CFTR function on mucin production in the gut remain poorly understood 
at this time. Most of the work has focused almost exclusively on lung cells and shown that in 
vitro CF airway models produce increased gel-forming mucin concentrations when compared to 
the WT controls. Our study provides a reliable in vitro gut model to explore the effects of CFTR 
function and loss-of-function on intestinal mucins. Additionally, our study identifies MUC2 as a 
permanently crosslinked mucin that remains tethered to cells in greater amounts than other 
secreted mucins. Pharmacological CFTR knockdown resulted in an increase in MUC5B but 
almost no change in MUC5AC concentration. The CFTR-knockout cell line, successfully 
generated by CRISPR, could further enlighten our findings. An improved understanding of CF 
mucin effects has the potential to be the key in developing genotype-independent treatments that 
may prevent disease progression and benefit all patients. 
Experimental Methods 
Cell Culture of HT29-MTX-E12 Cell line 
HT29-MTX-E12 cells (Sigma-Aldrich) were grown on a T75 cm2 culture-treated flask 
with 10 mL of media. They were incubated at 37°C, 5% CO2 with media changed every 2 or 3 
days. Once 90% confluent, the cells were rinsed with 1X PBS (Phosphate Buffered Saline) then 
detached with 0.25% EDTA-Trypsin. Cells were seeded in new flasks at a density of 5.0 x105 
cells. Media was prepared by adding 10% Fetal Bovine Serum (FBS), 1% Non-Essential Amino 
Acids (NEAA) and 1% Penicillin Streptomycin to DMEM Glutamax Low Glucose (1 g/L 
glucose, Low) base medium (ThermoFisher Scientific). For experimental testing, HT29 cells 
were seeded into six 12-well 12mm diameter transwell tissue-culture treated plates at a density of 
2.2x105 cells/cm2. Media were placed basolaterally (1.5 mL)  and apically (200 µL) until cells 
9 
	
reached confluence. Upon confluence, apical media was reduced to 100 µL to obtain semi-wet 
conditions. Basolateral and apical media were removed and replaced every 2-3 days. 
 
Characterization of HT29-MTX-E12 Cell line  
Media Name Glucose Concentration 
DMEM Glutamax High Glucose (High) 4.5 g/L 
DMEM Glutamax Low Glucose (Low) 1.0 g/L 
RPMI 1640 (RPMI) 2.0 g/L 
Table 1. Base Media Glucose Levels 
Different media conditions were prepared by adding 10% FBS, 1% NEAA, and 1% 
Penicillin Streptomycin to the base media (Table 1). The full recipes for the base media can be 
found in the appendix (Table A1). For comparison purposes, the same passage of cells were plated 
and grown in parallel with High, Low or RPMI media. Once confluent, half of the cultures for 
each media were treated with 10 µM of DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester) basolaterally for 4 days and placed on a rocker in the incubator to 
stimulate crypt differentiation.7   
At 2 days, 9 days, 16 days, and 23 days post-confluency, transepithelial electrical resistance 
(TEER) was measured with a World Precision Instruments Evom2 Epithelial Voltohmmeter. 
Different inserts were fixed for histological comparison or apical surfaces were washed for further 
analysis. 
Once cells reached maturity (28 days post-confluency), cell washings were collected and 
analyzed via dot blot for mucin production. Briefly, cell washings were applied via aspiration onto 
a nitrocellulose membrane. The membrane was washed and co-probed with a primary rabbit 
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polyclonal anti-MUC2 (H300) antibody and a mouse monoclonal anti-MUC5AC (45M1) antibody 
and revealed with fluorescently labeled secondary anti-rabbit (green) and anti-mouse (red) 
antibodies. Signal was captured using a LI-COR infrared imaging system and quantified using the 
Odyssey LI-COR software. 
 
CRISPR/Cas9 Plasmid Preparation and Lentivirus Production 
Once HT29-MTX-E12 media and culture conditions were optimized, we proceeded to use 
this cell line to investigate the mucin response to CFTR malfunction by knocking out CFTR in the 
cell line. This gene editing approach was conducted using the CRISPR/Cas9 non-homologous end-
joining method and encapsidation of the molecular tools (e.g., plasmids) into lentiviruses. To 
ensure an accurate retroviral target, two plasmids were obtained from abm Inc. (Figure 2). One 
plasmid carried the target sgRNA and Neomycin resistance (pLenti-U6-sgRNA-PGK-Neo), while 
the other plasmid carried the Cas9 and Puromycin resistance gene (pLenti-EF1a -Cas9-2A-Puro). 
For control, a plasmid similar to the first plasmid described above but containing a scrambled 
sgRNA was used to infect the cells. Amplifications of plasmids were achieved previously using 
the “α-Select Bronze Efficiency Chemically Competent Cells” kit (Bioline) via transformation and 
expansion. Plasmids were then purified using a QIAfilter maxi kit (QIAGEN) to extract DNA and 





Figure 2. Plasmids Construction and Sequencing of CRISPR Target. 
The plasmids containing guide RNA and Neomycin resistance were used to direct CRISPR insertion 
with addition of Cas9 with Puromycin resistance (A). Target 1 was selected initially with Targets 2 and 
3 made as backups (B). 
  
Once plasmid purification and sequencing were suitable, lentiviruses were prepared by 
mixing 1.75 mL of OptiMEM media with 7.5 mg of psVG packaging plasmid and 12 mg of 
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psPAX2 packaging plasmid. Additionally, 15 mg of purified plasmids (target or scrambled) was 
added and let mix for 5 minutes. A second mix was prepared with 3.5 mL of OptiMEM media and 
70 mL of X-tremeGENE reagent (Millipore Sigma). After incubation for 5 minutes at room 
temperature, 1.75 mL of the mix containing the X-tremeGENE reagent was added to each of the 
two plasmid mixes. These two solutions, called “CFTR Target 1” and “CFTR Scrambled Control” 
plasmid mixes, were then incubated at room temperature for 20 minutes. 
HEK cells were grown in DMEM base media with 10% FBS and 1% Penicillin 
Streptomycin until 80% confluent in a 15 cm culture treated plate. The two plasmid mixes were 
then added to the HEK cells separately and gently rocked to ensure even spread. Cells were 
returned to incubation at 37°C, 5% CO2 for 6 hours. After the 6 hours, media was removed and 
cells were washed once with 1x PBS. After washing, 30 mL of DMEM supplemented with 10% 
FBS, 1% BSA, and 10 mM HEPES were added to the cells. They were then returned to incubation 
for 60 hrs. At this time, virus titer levels were tested using a Takara test kit and the lentivirus 
product was collected. 
 
Lentivirus Transfection to Generate a HT29-MTX-E12-CFTR-KO Cell Line 
Before transfection, HT29 cells were seeded at a density of 5.0 x104 cells/well in a 6-well 
tissue culture treated plate. After 3 days, the cells were at 30% confluence and lentivirus infection 
was started. 1x106 Infectious Units of the Cas9 lentiviruses were added to four wells along with 3 
µL of Polybrene. Two of these wells were mixed with 1x106 Infectious Units of the CFTR Target 
1 lentivirus, and two different wells received 1x106 Infectious Units of the CFTR Scrambled 
Control lentivirus. The remaining two wells were kept as non-infected controls (WT). After 48 
hours, selection was started with 1 mg/mL of Geneticin and 2 mg/mL of Puromycin in all wells 
except one of the WT controls to monitor cell viability. Antibiotic treatment was kept for 2 weeks 
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and cells were passaged as they neared confluence. To ensure successful gene editing, CFTR gene 
and protein expression were tested via DNA sequencing and SDS- PAGE Western blotting, 
respectively. Ussing Chamber analysis was performed by Nancy Quinney of the UNC Gentzsch 
Lab. Changes in transepithelial voltage were measured following specific ion channel inhibitions 
(e.g., amiloride for ENaC and inhibitor 172 for CFTR) and gating (e.g., forskolin for CFTR), 
reflecting the accuracy of the model to mimic the intestinal epithelium.  
 
Pharmacological Inhibition of CFTR 
 In parallel, HT29 WT cells were treated with pharmacological agents (bumetanide and 5-
(N,N-dimethyl)-amiloride or DMA) to induce abnormal ionic fluxes and mimic CF conditions.25 
HT29 WT cells were seeded in transwells in a 6-well plate using Teflon spacers at a density of 2.0 
x 104 cells/cm2. After 28 days of culture, cell blisters or intercellular lumina (ITCL) (Figure 1B) 
were carefully removed, and the cells were allowed to regain tight junctions for 5 days. Inserts 
were treated apically with 10 mM Bumetanide and 100 mM DMA, while other inserts were used 
as WT controls, receiving 1x DMSO. Treatment occurred once a day for 3 days. Apical media 
secretions were then collected and run in a Western blot to detect MUC2, MUC5B, and MUC5AC 
secretion. Change in signal intensity was quantified using a t test in GraphPad Prism 7. 
 
Histology 
For all conditions, cells were fixed with 10% NBF at 1, 2, and 3 weeks post-confluence. 
Fixed cell inserts were sent to be processed and sectioned by the UNC Animal Histopathology 
Core. Sections were left unstained for immunohistochemistry or stained with Hematoxylin/Eosin 
(H&E) and Alcian Blue/Periodic Acid-Schiff (AB-PAS). Immunohistochemical staining was 
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performed with primary rabbit polyclonal anti-MUC2 (H300) and mouse monoclonal anti-
MUC5AC (45M1) fluorescent antibodies. 
Results 
HT29 MTX-E12 Characterization 
To determine optimal culture conditions, we tested six media conditions (DMEM high and 
low glucose and RPMI; all three media tested with and without DAPT and mechanical 
stimulation). To examine cell morphology, cells were fixed and processed via histology to monitor 
the formation of a columnar monolayer and mucus production over time. Observation of the 
histological sections stained via H&E under a light microscope revealed the presence of large 
ITCL blisters for all media conditions tested. DMEM high glucose conditions appeared the least 
uniform, with uneven cell surfaces, while DMEM low glucose and RPMI conditions provided 
smoother cell layers with the formation of a semi-polarized dome of cells at the center of the 
inserts. At week 3 post confluence with DMEM low glucose, some of the domes started to break 
apart or peel off, suggesting further differentiation and increased polarization. 
DAPT treatment increased goblet cell differentiation and mucus production, but the 2D 
cell layers lost their compact configuration. Instead of forming a semi-crypt morphology, the cell 
layer appeared less polarized with cells stacked on top of each other, resulting in an aberrant 
morphology (Figure 3). DMEM high glucose conditions also resulted in generally unpolarized 
cells, causing the mucus to spread throughout the cell layers. Cells grown in DMEM low glucose 
were semi-polarized with the formation of distinct ITCL. Prior to week 4 post confluence, DMEM 
low glucose allowed the formation of a cell monolayer but entrapped mucus in the ITCL with the 




Figure 3. HT29 Differentiated with Different Culture Conditions. 
Slides of WT HT29-MTX-E12 cells were fixed and stained with AB-PAS at 3 weeks post-confluence. 
High glucose DMEM Glutamax (High), RPMI 1640 (RPMI), and low glucose DMEM Glutamax 
(Low) media were tested resulting in differential cell columnar and blister growth. The addition of 
DAPT to is seen across the bottom row. 
 
Post differentiation, the cells grown in DMEM high glucose with and without DAPT 
showed detachment from their membrane and aberrant growth. In contrast, cells grown in DMEM 
low glucose in the absence of DAPT formed a semi-polarized columnar monolayer. 
Conditions using DMEM low glucose resulted in the greatest resistance while the DMEM 
high glucose conditions generally had the lowest TEER readings when measured with a WPI 
Evom2 (Figure 4A). This shows that the cells grown in DMEM low glucose formed tight junctions 
quicker and retained a stronger seal across the membrane. The inserts reached maximum resistance 
around one to two weeks, which correlated with peak blister seal. The higher the glucose 
concentration, the lower the resistance; cells grown in RPMI had intermediate resistance readings 
but were comparable to that of high glucose conditions. The relationship between DAPT treatment 
and resistance was more variable and remains unclear. A follow-up assessment that measured 
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resistance post differentiation and blister removal comparing DMEM low glucose with RPMI 
showed that cells grown in DMEM low glucose media recovered quicker and retained higher 
resistance (Figure 4B). 
 




Figure 4. Resistance Change with Differentiation in Media Conditions.  
A) TEER measured by WPI EVOM2 revealed changes over a 4-week period for all media 
conditions tested to growing HT29-MTX-E12 cells. *Asterisks indicate treatment with DAPT 
and mechanical stimulation.  
B)  TEER measurement post removal of the ITCL blister for cells grown in DMEM low glucose 
or RPMI media (1 and 2 reflect two different inserts of the same condition).  
 
 
To quantify relative mucin production, we used dot blotting on apical cell washings over 
time. Each of the media conditions produced a relatively similar concentration of MUC5AC 
(Figure 5). Of all the conditions, DMEM low glucose initially showed the highest production of 
MUC5AC, but after roughly two weeks, this condition showed the lowest levels of MU5AC. 
DMEM high glucose produced the the most consistent and sustained MUC5AC production and an 
intermediate amount of MUC2. While pipetting, cells grown under DMEM high glucose appeared 
to have the most viscous mucus, but cells grown under low glucose ended up producing more 
MUC2, suggesting that MUC5AC possesses higher viscoelastic properties than MUC2. DAPT 
treatment slightly stimulated MUC2 production, but its effect on MUC5AC production is unclear. 
Overall, DMEM low glucose without DAPT provides the best results with a high concentration of 




MUC2 Apical Media Concentration
 
MUC5AC Apical Media Concentration
 
Figure 5. Mucin Production under the Different Media Conditions. 
A) Dot blot assay shows the relative change in MUC2 production for each condition over several 
days (0-36) of culture.  
B) Relative signal intensity by dot blot for the mucin MUC5AC for each condition over several 
days (0-36) of culture.  
*Asterisks indicate treatment with DAPT and mechanical stimulation. 
 
 The results showed that over time, wildtype HT29 cells produced an increasing amount of 
both MUC5AC and MUC2. While MUC5AC was clearly present in apical washings, MUC2 
appeared to be at lower concentrations. However, cell lysates analyzed by Western blotting 
revealed that both mucins, especially MUC2, were at higher levels intracellularly or attached to 
the cell surfaces (Figure 6B). Immunohistochemistry revealed that MUC2 was located inside 
mucin granules that were clustered rather than coating the cell surfaces (Figure 6A). Additionally, 
MUC2 and MUC5AC signals did not co-localize, which could suggest different machineries or 








Figure 6. Immunohistochemistry and Western blotting to detect Mucin Localization and 
Production in Cultures.  
A) HT29 cultures were fixed, processed for histology, and sections were stained with a rabbit anti-
MUC2 (H300) (green) or a mouse anti-MUC2 (BD) (red) antibody.   
B) Western blot of HT29 washings, cell and blister lysates, showing signal for MUC2 (top blot) 
and MUC5AC (bottom blot) production. 3 cell washings were run for week 1 (A), week 5 (B), 
and week 3 (C). 3 cell lysates were run for week 3 (D) and 2 blister lysates for week 4 (E). 
	
Ussing chamber results from a preliminary study were inconclusive with the HT29 cell 
line, but the same cells cultured in DMEM low glucose media without DAPT maintained CFTR 
function (Figure A2). The absence of distinct peaks suggested issues regarding CFTR expression 
and pharmacological inhibition for all the tested conditions. 
	
CRISPR/Cas9 gene editing to create a HT29 MTX-E12 CFTR-KO cell line 
In order to mimic a CF environment, we generated a CFTR knockout line of HT29-MTX-
E12, using the CRISPR/Cas9 NHEJ approach. This method necessitated we acquired and purified 
plasmids with the target sequence and antibiotic resistance to encapsulate into lentiviruses. These 
lentiviruses were used to transfect WT cells, which were then treated with antibiotics to eliminate 
cells where transfection was unsuccessful. Antibiotic selection resulted in the death of all selected 
wild type cells while those transfected with either CFTR Scrambled Control or CFTR Target 1 
survived. Unselected wildtype cells continued to survive and reach confluence quickly identifying 
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the antibiotic selection as the differing factor (Figure 7A). The CFTR Target 1 cells were then 
sequenced and analyzed for CFTR protein. Sequencing showed almost no presence of unaltered 
CFTR DNA, and SDS-PAGE showed a lack of a band of CFTR protein in the knockout identifying 






Figure 7. Virus Transfection and Knockout Generation. 
A) The left column of wells tested the selection of the Geneticin and Puromycin antibiotics. The 
center column of wells shows Control transfection cell growth under selection, and the right 
column shows Target 1 transfected cell growth with selection. 
B) SDS-PAGE of cell lysates and DNA sequencing show CFTR protein level (band just below 
250) and aberrant CTFR sequence respectively.  
	
 While generating the CFTR KO cell line, wildtype cells were used to mimic disease state 
through pharmacological inhibition of CFTR. This inhibition provided a temporary model to 
investigate short term mucin changes. Pharmacological inhibition resulted in an increase in mucins 
quantified by Western blot (Figure 8). While MUC5AC did not significantly increase in the 
chemically knocked down cells, MUC5B did significantly increase. MUC2 appears to have a 




Figure 8. Pharmacological Inhibition of CFTR Affects Mucin Concentrations. 
GraphPad Prism7 t-test analysis and boxplots quantify mucin concentrations of HT29 apical media 





 Our goal was to better characterize intestinal mucus and to generate a model that was 
optimized to study pure mucins in vitro.  Current literature mainly focuses on airway mucus 
response to CFTR malfunction, while the systemic problem of aberrant mucus phenotype in 
several organs in CF suggests that all gel-forming mucins develop aberrant properties in CF. 
Studies not related to CF have suggested that intestinal cultures treated with DAPT, mechanical 
stimulation, and high levels of glucose may generate a model more similar to in vivo conditions.7&8 
With this work, we demonstrated that HT29-MTX-E12 can fill the void and be appropriately used 
as an intestinal in vitro model. Cultures in low glucose media without the presence of DAPT and 
mechanical stimulation resulted in optimal mucus production and histology, and genetic 
manipulation to generate a CFTR knockout HT29 cell line mimicking the CF environment was 
successful. 
DMEM low glucose media resulted in the tightest polarized monolayer of cells. 
Additionally, this media condition resulted in the highest membrane resistance, and the cells were 
able to recover after ITCL blister removal. RPMI resulted in intermediate TEER values, which 
may be due in part to the presence of L-Glutamine affecting tight junctions. An RPMI Glutamax 
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media could have resulted in slightly higher resistance due to less ammonia generation and cell 
damage, but this does not seem to be as important of a factor as glucose concentration.  DMEM 
low glucose media produced the highest concentration of MUC2 and an average MUC5AC 
concentration. While DAPT increased mucin concentrations, it resulted in abnormal histology due 
to cell metaplasia. Antibody staining showed that MUC2 is in much higher concentration 
intracellularly or tethered to the cells than detected in the lumen in the secreted form. The CFTR 
CRISPR/Cas9 transfected cells survived through selection and showed an absence of functional 
CFTR while the WT, untransfected cells did not survive antibiotic selection as expected. 
Pharmacological inhibition of CFTR resulted in increases of some mucins (MUC2 & MUC5B), 
but MUC5AC remained relatively unchanged. 
 Overall, low glucose DMEM Glutamax media without DAPT or mechanical stimulation 
provided the best results for cell growth and mucin production. It was the only media in which 
cells fully differentiated to a monolayer without dying or losing polarity. The resulting high MUC2 
levels in low glucose media are ideal as this is the major mucin of the gut and crucial for studying 
mucin properties. The presence of an intermediate, average concentration of MUC5AC is also 
important as it has comparative levels with lung mucus. The higher resistance seen in low glucose 
media additionally suggests its superiority as a model with stronger tight junctions necessary for 
investigating ion transport. 
 Our findings diverge from recent literature as DAPT and mechanical stimulation resulted 
in poor growth and less stability. Our suspicions were supported as well that lower glucose slows 
growth and results in a preferable polarized monolayer. Ussing results were inconclusive on how 
these conditions affected CFTR. This was likely due to the cells’ semi-polarized nature with ITCL 
blisters interrupting directional CFTR ion transfer. 
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 Investigation of mucin localization supported the idea that MUC2 may remain either within 
granules or stay tethered to cell membranes. The high concentration and visualization inside cells 
reinforces this idea suggesting additional steps may be taken naturally when releasing the mucin. 
While MUC2 is classified as a secreted gel forming mucin, our data shows that it may take a 
different path to secretion resulting in difficulty measuring mucin level if it remains attached. This 
finding could potentially impact past results if the level of MUC2 present does not match what 
was collected. 
 The CRISPR/Cas9 knockout was successful in interrupting the CFTR gene. This resulted 
in a cell line devoid of CFTR that can function as a CF model. Combined with other findings of 
histology, adequate mucus levels, and CFTR response in WT cells, the HT29 transfected cells 
provide a key model to further investigate direct mucus effects of CF. The pharmacological 
inhibition provides an alternate model in which CFTR is temporarily inactivated. This matched 
with previous studies of airway cells showing an increase in mucus, but interestingly MUC5AC 
concentration remained the same. Cystic Fibrosis may not affect MUC5AC unanimously across 
the body. MUC2 levels showed a decrease when quantified but this is likely due to either mucins 
unable to transfer through the agarose gel in the western blot due to their complex polymerization 
network or due to remaining tethered to cells.  
 Successful optimization and transfection of the HT29 cell line as a gut model allows for 
future directions in developing a mucin-based, genotype independent treatment for CF and other 
mucus based diseases. While traditional Ussing chamber exploration has been inconsistent with 
HT29 cells, FLIPR, a method of fluorescently labeling functioning CFTR, could provide more 
clarity. Our next steps will be to introduce specific mutations into the CFTR knockout line to 
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Glutamax RPMI 1640 
Components mM mM mM 
Amino Acids    
Glycine 0.4 0.4 0.13333334 
L-Alanyl-Glutamine 3.9723501 3.9723501  
L-Arginine   1.1494253 
L-Arginine hydrochloride 0.39810428 0.39810428  
L-Asparagine   0.37878788 
L-Aspartic acid   0.15037593 
L-Cystine  0.15335463  
L-Cystine 2HCl 0.20127796  0.20766774 
L-Glutamic Acid   0.13605443 
L-Glutamine   2.0547945 
L-Histidine   0.09677419 
L-Histidine hydrochloride-H2O 0.2 0.2  
L-Hydroxyproline   0.15267175 
L-Isoleucine 0.8015267 0.8015267 0.3816794 
L-Leucine 0.8015267 0.8015267 0.3816794 
L-Lysine hydrochloride 0.7978142 0.7978142 0.21857923 
L-Methionine 0.20134228 0.20134228 0.10067114 
L-Phenylalanine 0.4 0.4 0.09090909 
L-Proline   0.17391305 
L-Serine 0.4 0.4 0.2857143 
L-Threonine 0.79831934 0.79831934 0.16806723 
L-Tryptophan 0.078431375 0.078431375 0.024509804 
L-Tyrosine  0.39779004  
L-Tyrosine disodium salt dihydrate 0.39846742  0.11111111 
L-Valine 0.8034188 0.8034188 0.17094018 
Vitamins    
Biotin   8.20E-04 
Choline chloride 0.028571429 0.028571429 0.021428572 
D-Calcium pantothenate 0.008385744 0.008385744 5.24E-04 
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Folic Acid 0.009070295 0.009070295 0.002267574 
Niacinamide 0.032786883 0.032786883 0.008196721 
Para-Aminobenzoic Acid   0.00729927 
Pyridoxine hydrochloride 0.019417476 0.019417476 0.004854369 
Riboflavin 0.00106383 0.00106383 5.32E-04 
Thiamine hydrochloride 0.011869436 0.011869436 0.002967359 
Vitamin B12   3.69E-06 
i-Inositol 0.04 0.04 0.19444445 
Inorganic Salts    
Calcium Chloride (CaCl2) (anhyd.) 1.8018018   
Calcium Chloride (CaCl2-2H2O)  1.7959183  
Calcium nitrate (Ca(NO3)2 4H2O)   0.42372882 
Ferric Nitrate (Fe(NO3)3"9H2O) 2.48E-04 2.48E-04  
Magnesium Sulfate (MgSO4) (anhyd.) 0.8139166  0.407 
Magnesium Sulfate (MgSO4-7H2O)  0.8130081  
Potassium Chloride (KCl) 5.3333335 5.3333335 5.3333335 
Sodium Bicarbonate (NaHCO3) 44.04762 44.04762 23.809525 
Sodium Chloride (NaCl) 110.344826 110.344826 103.44827 
Sodium Phosphate dibasic (Na2HPO4) anhydrous  5.633803 
Sodium Phosphate monobasic (NaH2PO4-H2O) 0.9057971 0.90384614  
Other Components    
D-Glucose (Dextrose) 25 5.5555553 11.111111 
Glutathione (reduced)   0.003257329 
Phenol Red 0.039851222 0.039851222 0.013283741 





Figure A2. Ussing chamber current signifies CFTR function 
HT29-MTX-E12 cells grown under DMEM low glucose conditions (left) and DMEM high glucose 
(right) show current changes in response to CFTR modulators in an Ussing chamber. 
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